Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial

OBJECTIVE: The aim of this study was to evaluate efficacy and safety of everolimus in patients with pancreatic neuroendocrine tumors (pNET) by prior chemotherapy use in the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3). METHODS: Patients with advanced, progressive, low- or interm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombard-Bohas, Catherine, Yao, James C., Hobday, Timothy, Van Cutsem, Eric, Wolin, Edward M., Panneerselvam, Ashok, Stergiopoulos, Sotirios, Shah, Manisha H., Capdevila, Jaume, Pommier, Rodney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327560/
https://www.ncbi.nlm.nih.gov/pubmed/25479584
http://dx.doi.org/10.1097/MPA.0000000000000262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327560/
https://www.ncbi.nlm.nih.gov/pubmed/25479584
http://dx.doi.org/10.1097/MPA.0000000000000262

Ejemplares similares